Effects of artificial oocyte activation with A23187 versus ionomycin on clinical outcomes
10.3760/cma.j.cn101441-20200524-00304
- VernacularTitle:两种钙离子载体A23187和离子霉素对卵母细胞激活效果的比较
- Author:
Lei JIA
1
;
Shujing HE
1
;
Wenlong SU
1
;
Yingchun GUO
1
;
Yi ZHOU
1
;
Cong FANG
1
Author Information
1. 中山大学附属第六医院生殖医学研究中心，广州510655
- Publication Type:Journal Article
- Keywords:
Artificial oocyte activation;
A23187;
Ionomycin
- From:
Chinese Journal of Reproduction and Contraception
2021;41(5):432-439
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To compare the fertilization rate, embryonic developmental potential, and clinical outcomes following the applications of A23187 and Ionomycin.Methods:A total of 65 patients whose oocytes were exposed to either the A23187 or Ionomycin for artificial oocyte activation (AOA) due to total failed fertilization/lower fertilization rate in the previous intracytoplasmic sperm injection (ICSI) cycles or severe oligo-astheno-teratozoospermia at Reproductive Medicine Research Center of the Sixth Affiliated Hospital of Sun Yat-sen University from May 2010 to December 2019 were enrolled in this retrospective cohort study. All patients were categorized into two groups: A23187-AOA group and Ionomycin-AOA group. And each group was divided into two subgroups according to sperm origin (ejaculated or testicular sperm). The fertilization rate, embryo development potential and clinical outcome were compared between the two groups.Results:The two pronuclei (2PN) fertilization rate [55.0% (116/211) vs. 43.3% (135/312), P=0.008], 2PN cleavage rate [97.4% (113/116) vs. 90.4% (122/135), P=0.023] and blastocyst formation rate [69.1% (38/55) vs. 45.2% (14/31), P=0.029] in the Ionomycin-AOA group were significantly higher than those in the A23187-AOA group. In the ejaculated spermatozoa subgroup, the 2PN cleavage rate [97.1% (68/70) vs. 85.8% (91/106), P=0.013] and the rate of day 3 (D3) transferable embryos [92.6% (63/68) vs. 73.6% (67/91), P=0.002] in the Ionomycin-AOA group were higher than those in the A23187-AOA group; in the testicular spermatozoa subgroup, the 2PN fertilization rate [55.4% (46/83) vs. 37.7% (29/77), P=0.024], the blastocyst formation rate [93.3% (14/15) vs. 20.0% (1/5), P=0.005], the implantation rate [38.9% (7/18) vs. 5.6% (1/18), P=0.041] and the cumulative clinical pregnancy rate [66.7% (6/9) vs. 10.0% (1/10), P=0.019] in the Ionomycin-AOA group were higher than those in the A23187-AOA group. A total of 20 healthy neonates were delivered in 65 patients. None of the congenital anomalies (birth defects) was found in fetuses after AOA. Conclusion:Ionomycin may be superior to A23187 for improving fertilization rate and embryonic developmental potential. And compared with A23187, Ionomycin may be a more efficient means to benefit the patients with testicular-origin severe oligo-astheno-teratozoospermia.
